In response to this robust performance, Bausch + Lomb raised its full-year 2024 guidance. The company now projects revenue in the range of $4.700 billion to $4.800 billion, representing a constant ...

Bausch + Lomb Corp. announced June 30 that it will acquire XIIDRA, a treatment for dry eye disease, from Novartis for up to $2.5 billion.

Anyone seeking to report adverse effects should contact Bausch + Lomb at 800-338-2020, option 1, or submit a report to the FDA’s MedWatch program (800-332-1088 to request a form).

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Bausch + Lomb drug Miebo is now FDA approved as a new treatment for dry eye disease. Unlike many products that rewet the eye, Miebo is designed to address one of the factors that leads to dry eyes.

Bausch + Lomb is down 17.9% since the beginning of the year, and at $14.78 per share, it is trading 29.4% below its 52-week high of $20.93 from October 2024.

Bausch + Lomb Corp. announced July 20 that Chairman and CEO Joseph Papa stepped down as chair of the company’s board of directors. The board appointed Thomas Ross Sr. to serve as chair and has ...

Bausch + Lomb has obtained fully committed financing from J.P. Morgan for the transaction and intends to finance the $1.75 billion upfront cash purchase price with new debt prior to closing.

Bausch Health ’s four-year-old plan to spin off eye-care subsidiary Bausch + Lomb is caught in a standoff between the pharmaceutical company’s top shareholders including Carl Icahn and Paulson ...

Bausch Health Companies (BHC), the parent company of Bausch + Lomb, announced in 2020 its plans to spin off the eye health business as an independent and publicly traded company.